Excessive Daytime Sleepiness (EDS) is characterized by a difficulty to stay awake and alert during the major waking episodes of the day, with sleep occurring unintentionally or at inappropriate times of the wake period.
Excessive Daytime Sleepiness (EDS) can be harder to identify in children, as it can look different from how it appears in adults. Older children may start retaking naps, and younger children may start taking longer naps or extending their night-time sleep. The diagnosis of Excessive Daytime Sleepiness (EDS) include questionnaires, identification of underlying medical condition, and diagnosis testing [i.e., Epworth Sleepiness Scale (ESS), Multiple Sleep Latency Test (MSLT), and Maintenance of Wakefulness Test (MWT)].
Excessive Daytime Sleepiness (EDS) Market key facts
The total diagnosed prevalent population of Excessive Daytime Sleepiness (EDS) in these five disorders [(i.e Parkinson’s disease (PD), Narcolepsy, Idiopathic Hypersomnia (IH), Obstructive Sleep Apnea (OSA), and Bipolar Disorder (BD)] in the 7MM was estimated to be 6,295,782 in 2017.
In 2017, the diagnosed prevalent population of Excessive Daytime Sleepiness (EDS) in the United States was 2,960,518. Among the 7MM, the highest cases of Excessive Daytime Sleepiness (EDS) were diagnosed in the US, in comparison to EU-5 and Japan.
As per the DelveInsight analysis, it is observed that Japan has the second-highest diagnosed prevalent population of Excessive Daytime Sleepiness (EDS), among 7MM. As per DelveInsight’s estimates, Japan accounts for approximately 22.40% of the total diagnosed prevalent cases in the 7MM.
DelveInsight's "Excessive Daytime Sleepiness (EDS) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Excessive Daytime Sleepiness (EDS) Market, historical and forecasted epidemiology, the pipeline insight as well as the Excessive Daytime Sleepiness (EDS) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan
Excessive Daytime Sleepiness (EDS) Market Share and Trends Analysis
The Excessive Daytime Sleepiness (EDS) market size is expected to grow during the forecast period owing to the factors like an increase in the patient pool due to a rise in the prevalence of underlying medical conditions, and expected entry of emerging therapies.
The Excessive Daytime Sleepiness (EDS) market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Excessive Daytime Sleepiness (EDS) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Excessive Daytime Sleepiness (EDS) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Excessive Daytime Sleepiness (EDS) Epidemiology Forecast
The Excessive Daytime Sleepiness (EDS) epidemiology section covers insights about historical and current Excessive Daytime Sleepiness (EDS) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Excessive Daytime Sleepiness (EDS) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Some of the key Excessive Daytime Sleepiness (EDS) companies involved in developing therapies for the treatment include:
BenevolentAI Bio
Avadel Pharmaceuticals
Theranexus
Jazz Pharmaceuticals
Axsome Therapeutics
Bioprojet Pharma
Harmony Biosciences
Suven Life Sciences
And many others.
For more details, visit: Excessive Daytime Sleepiness (EDS) Market Share and Trends Analysis